Cambridge, Mass.— GC Therapeutics (GCTx), a biotechnology company focused on advancing iPSC-based cell therapies, has expanded its leadership team with the appointment of two industry veterans. The company announced Monday that Kai-Hsin Chang, Ph.D., has joined as Senior Vice President and Head of Drug Development, while Azadeh Golipour, Ph.D., will serve as Senior Vice President and Head of Technical Operations.
Dr. Chang, formerly of Editas Medicine, brings significant experience in drug development, regulatory strategy, and translational medicine. At Editas, she played a pivotal role in advancing genome-editing therapies through key preclinical and clinical stages, including multiple Investigational New Drug (IND) submissions. Her appointment is expected to bolster GC Therapeutics’ development pipeline and strategic planning.
“I am excited to join GC Therapeutics at such a transformative stage,” said Chang. “The company’s TFome™ platform presents a unique opportunity to deliver breakthrough therapies to patients. I look forward to working with a team that is redefining the future of cell therapy.”
Dr. Golipour, who previously led technical operations at AVROBIO, has overseen the development and scaling of gene and cell therapies from discovery through clinical manufacturing. At GC Therapeutics, she will lead efforts to advance scalable manufacturing solutions for the company’s off-the-shelf allogeneic therapies.
“GC Therapeutics is uniquely positioned to transform the field of cell therapy,” said Golipour. “The company’s differentiated technology enables rapid and efficient manufacturing, and I’m excited to help bring these innovations closer to patients.”
Parastoo Khoshakhlagh, Ph.D., CEO and co-founder of GC Therapeutics, said the appointments mark a critical step forward for the company.
“Kai-Hsin and Azadeh are exceptional leaders whose experience will be vital in accelerating our mission to develop next-generation cell therapies,” Khoshakhlagh said. “Their contributions will help drive our vision of making transformative treatments widely accessible.”
GC Therapeutics is developing iPSC-based therapies powered by its proprietary TFome™ platform, aiming to deliver scalable, allogeneic treatments for a range of serious diseases.
